Scarica l'app Stockscreener
25.86
2.95%
0.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$25.12
Aprire:
$25.09
Volume 24 ore:
3.27M
Relative Volume:
1.27
Capitalizzazione di mercato:
$3.27B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-12.74
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+3.56%
1M Prestazione:
+25.17%
6M Prestazione:
+45.12%
1 anno Prestazione:
-22.01%
Intervallo 1D:
$25.00
$26.24
Intervallo di 1 settimana:
$24.56
$26.24
Portata 52W:
$16.10
$35.57
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
25.86 | 3.18B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Resistance Check: Is Apellis Pharmaceuticals Inc stock cheap at current valuation2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersSector Performance Review & Superior Capital Investment - bollywoodhelpline.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN
Simplify Asset Management Inc. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Institution Moves: How buybacks impact Apellis Pharmaceuticals Inc stock valueJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - moha.gov.vn
Apellis Pharmaceuticals' chief commercial officer sells shares worth $101,103 - MSN
Understanding Momentum Shifts in (APLS) - Stock Traders Daily
Highland Capital Management LLC Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Earnings Notes - Trefis
How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - bollywoodhelpline.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX) - The Globe and Mail
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating - 富途牛牛
Will Apellis Pharmaceuticals Inc. (1JK) stock outperform foreign stocksEarnings Risk Report & Reliable Volume Spike Trade Alerts - Улправда
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekersWeekly Trade Recap & High Conviction Buy Zone Picks - Улправда
Will Apellis Pharmaceuticals Inc. stock see PE expansion2025 Trading Recap & Reliable Price Breakout Signals - Улправда
Stifel maintains Apellis Pharmaceuticals (APLS) buy recommendation - MSN
APLS (Apellis Pharmaceuticals) EV-to-OCF : 39.23 (As of Dec. 19, 2025) - GuruFocus
Apellis Pharmaceuticals stock price target lowered to $48 at Stifel By Investing.com - Investing.com Canada
Stifel Lowers Price Target for Apellis Pharmaceuticals (APLS) to $48 | APLS Stock News - GuruFocus
Stifel Nicolaus Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00 - MarketBeat
Is Apellis Pharmaceuticals Inc. stock near bottom after decline2025 Pullback Review & AI Forecasted Entry and Exit Points - DonanımHaber
What technical charts say about Apellis Pharmaceuticals Inc. stock2025 Technical Overview & Comprehensive Market Scan Insights - Улправда
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 5,000 Shares of Stock - MarketBeat
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
Officer Watson Sells 5,000 ($122.5K) Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Investors in Apellis Pharmaceuticals (NASDAQ:APLS) From Five Years Ago Are Still Down 54%, Even After 3.2% Gain This Past Week - 富途牛牛
Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
Hudson Bay Capital Management LP Has $8.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis stock rating reiterated at Outperform by William Blair - Investing.com Canada
Squarepoint Ops LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Braidwell LP Sells 531,300 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
683 Capital Management LLC Buys 77,000 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha
Natixis Sells 564,361 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Camber Capital Management LP Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Low Cost Wealth Building - earlytimes.in
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Apellis Pharmaceuticals, Inc. $APLS Shares Purchased by Amundi - MarketBeat
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Would You Still Hold Apellis Pharmaceuticals Stock If It Fell 30%? - Trefis
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis shares jump 12% following FDA approval of first-ever C3G treatment - MSN
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):